Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The inaccurate rumours refer to a study looking at excess deaths during the pandemic in the German city of Frankfurt am Main.

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

The world's first mRNA vaccine against Elephant Endotheliotropic Herpesvirus (EEHV) has reportedly shown promising results, ...

Professor Hirohide Saito (Department of Life Science Frontiers at CiRA / The University of Tokyo) and Assistant Professor ...